Hormone replacement therapy

BMJ (Online)

Volumn 344, Issue 7845, 2012, Pages 44-49

  Hickey, Martha ^a   Elliott, Jane ^b   Davison, Sonia Louise ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CONJUGATED ESTROGEN; DESVENLAFAXINE; ESCITALOPRAM; ESTRADIOL; ESTROGEN; ESTRONE; FLUOXETINE; GABAPENTIN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PLACEBO; TESTOSTERONE; TIBOLONE; VENLAFAXINE;

ADULT; ARTICLE; ATROPHIC VAGINITIS; BLEEDING; BREAST CANCER; BREAST TENDERNESS; CARDIOVASCULAR DISEASE; CASE REPORT; CHOLECYSTITIS; CLINICAL FEATURE; CONSENSUS SEQUENCE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG SAFETY; ENDOMETRIUM CANCER; FEMALE; GALLBLADDER CANCER; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LOW DRUG DOSE; MENOPAUSAL SYNDROME; MENOPAUSE; NIGHT SWEAT; PRIORITY JOURNAL; QUALITY OF LIFE; RELAXATION TRAINING; RISK BENEFIT ANALYSIS; SLEEP DISORDER; STROKE; SYMPTOMATOLOGY; THROMBOEMBOLISM; TREATMENT INDICATION; VAGINAL DRYNESS; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM;

EID: 84857563474     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e763     Document Type: Article

References (38)

1. Furness S, Roberts H, Marjoribanks J, Lethaby A, Hickey M, Farquhar C. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev 2009;2:CD000402.
2. Politi MC, Schleinitz MD, Col NF. Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. J Gen Intern Med 2008;23:1507-13.
3. MacLennan AH, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;4:CD002978.
4. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33. (Pubitemid 34761611)
5. Welton AJ, Vickers MR, Kim J, Ford D, Lawton BA, MacLennan AH, et al. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ 2008;337:1190.
6. Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95(7 suppl 1):s1-66.
7. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-41. (Pubitemid 32003509)
8. Hammar ML, van de Weijer P, Franke HR, Pornel B, von Mauw EM, Nijland EA, et al. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. BJOG 2007;114:1522-9. (Pubitemid 350077436)
9. Egarter C, Topcuoglu A, Vogl S, Sator M. Hormone replacement therapy with tibolone: effects on sexual functioning in postmenopausal women. Acta Obstet Gynecol Scand 2002;81:649-53. (Pubitemid 34827875)
10. Sturdee DW, Pines A. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 2011;14:302-20.
11. Gompel A, Rozenberg S, Barlow DH, EMAS board members. The EMAS 2008 update on clinical recommendations on postmenopausal hormone replacement therapy. Maturitas 2008;61:227-32.
12. Estrogen and progestogen use in postmenopausal women: 2010 position statement of North American Menopause Society. Menopause 2010;17:242-55.
13. Sare GM, Gray LJ, Bath PM. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J 2008;29:2031-41.
14. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Lévesque H, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;113:840-5. (Pubitemid 46294724)
15. Wu O, Robertson L, Twaddle S, Lowe GD, Clark P, Greaves M, et al. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess 2006;10(11):1-110.
16. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002;288:872-81.
17. Renoux C, Dell'aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010;340:c2519.
18. Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P et al. The effects of tibolone in older postmenopausal women. N Engl J Med 2008;359:697-708.
19. Harman SM, Vittinghoff E, Brinton EA, Budoff MJ, Cedars MI, Lobo RA, et al. Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. Am J Med 2011;142:199-205.
20. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010;304:1684-92.
21. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27. (Pubitemid 36999703)
22. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-53. (Pubitemid 37430077)
23. Archer DF, Hendrix S, Gallagher JC, Rymer J, Skouby S, Ferenczy A, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab 2007;92:911-8. (Pubitemid 46465662)
24. Liu B, Beral V, Balkwill A, Green J, Sweetland S, Reeves G, et al. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ 2008;337:a386.
25. Lekander I, Borgström F, Ström O, Zethraeus N, Kanis JA. Cost-effectiveness of hormone therapy in the United States. J Womens Health (Larchmt) 2009;18:1669-77.
26. Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009;10:135-46.
27. Bousser MG, Conard J, Kittner S, de Lignieres B, MacGregor EA, Massiou H, et al. Recommendations on the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. The International Headache Society Task Force on Combined Oral Contraceptives and Hormone Replacement Therapy. Cephalalgia 2000;20:155-6. (Pubitemid 32269502)
28. Lekander I, Borgström F, Ström O, Zethraeus N, Kanis JA. Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK. Menopause Int 2009;15(1):19-25.
29. Maki PM, Freeman EW, Greendale GA, Henderson VW, Newhouse PA, Schmidt PJ, et al. Summary of the National Institute on Aging-sponsored conference on depressive symptoms and cognitive complaints in the menopausal transition. Menopause 2010;17:815-22.
30. Gebbie AE, Hardman SM. Contraception in the perimenopause-old and new. Menopause Int 2011;16(1):33-7.
31. Rada G, Capurro D, Pantoja T, Corbalán J, Moreno G, Letelier LM, et al. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev 2011;9:CD004923.
32. Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010;340:c693.
33. Reddy SY, Warner H, Guttuso T Jr, Messing S, DiGrazio W, Thornburg L, et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006;108:41-8. (Pubitemid 44336843)
34. Aguirre W, Chedraui P, Mendoza J, Ruilova I. Gabapentin vs. low-dose transdermal estradiol for treating post-menopausal women with moderate to very severe hot flushes. Gynecol Endocrinol 2010;26:333-7.
35. Hunter M, Mann E. A cognitive model of menopausal hot flushes and night sweats. J Psychosom Res 2010;69:491-501.
36. Borrelli F, Ernst E. Alternative and complementary therapies for the menopause. Maturitas 2010;66:333-43.
37. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women (review). Cochrane Database Syst Rev 2006;4:CD001500.
38. Sturdee DW, Panay N, International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010;13:509-22.